NEURONETICS INC. DL-,01

Neuronetics posted Q2 revenue of $41.6 million, up ~9% year-over-year, driven by Greenbrook clinics ($26.9 million, +16.8%) while NeuroStar revenue declined to $14.7 million as the company shifts customers from a session model toward capital sales and leasing. Gross margin improved to 51.1% and adjusted EBITDA was positive $0.3 million, with net loss narrowing to $3.4 million; cash totaled $25 million at quarter end after $7.6 million raised via an ATM. Management narrowed full-year revenue guidance to $160–164 million, lowered OPEX guidance and expects reduced cash burn as it scales Greenbrook, rolls out new NeuroStar commercial options and pursues interventional psychiatry opportunities. » More on finance.yahoo.com

For Q2 2026 Neuronetics reported revenue of $41.6 million (+9.1% y/y) and a net loss of $3.4 million (‑$0.05 per share), markedly better than the consensus estimate of about ‑$0.12. The clinic segment Greenbrook contributed $26.9 million (+16.8%) and was a key driver of growth; adjusted EBITDA improved to $0.3 million versus ‑$5.6 million a year earlier, and the cash outflow from operating and investing activities fell to $1.4 million. Management changes, including a new CFO, boosted confidence in the turnaround strategy, after which the stock rose about 24% in premarket trading. » More on de.investing.com

Neuronetics has revised the adviser agreement with interim Principal Financial and Accounting Officer Francis X. Brown III effective May 18, 2026; Brown will remain in office until a full-time controller and head of finance is appointed or until a mutually agreed written date. Compensation was adjusted from $25,000 to a monthly flat fee of $26,000. The company also reported Q1 2026 revenue of $34.5 million (above analyst expectations) but missed the EPS target; Neuronetics announced a partnership with ANT Neuro to integrate neuronavigation technology. » More on de.investing.com